Treatment News : HIV Drug Isentress Could Fight All Herpes Viruses

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 24, 2010

HIV Drug Isentress Could Fight All Herpes Viruses

The integrase inhibitor Isentress (raltegravir) could lead to the development of an effective treatment against all herpes viruses, including strains that can cause blindness and cancer, according to an announcement by researchers from the Institute for Research in Biomedicine (IRB) in Barcelona. The researchers’ complete findings were published online August 30 in the Proceedings of the National Academy of Sciences.

Miquel Coll, PhD, the senior author of the paper and a researcher at the IRB, has been working for some time with his fellow researchers to help resolve the structural proteins that help herpes viruses reproduce.

The herpes family includes herpes simplex, which can cause oral or genital ulcers; herpes zoster (varicella), which causes chickenpox and shingles; Epstein-Barr virus, which is associated with several types of cancer; cytomegalovirus, which can lead to blindness and potential worsen the course of HIV disease; and Human Herpes Virus-8, which can cause Kaposi’s sarcoma.

One step in the herpes replication process takes place within the nucleus of a target human cell, where the human DNA is contained. The herpes virus is able to hijack the human DNA to make long strands of viral DNA. To form new infectious viruses, however, these long DNA strands must be chopped up and repackaged. The molecular complex responsible for this process is called terminase, and that’s where Coll and his colleagues have been focusing, as this complex is shared by all of the herpes family of viruses.

When the researchers built a 3D model of the terminase, they realized that it strongly resembled the HIV integrase protein of HIV. Given that Isentress binds to this protein, and is an approved drug with a known safety profile, Coll’s group next explored whether Isentress would bind to the herpes terminase, which it did. The next step is to test Isentress in cell cultures and determine its effect on a variety of herpes strains.

“These results have a clear medical impact,” Coll said. “Now we must do the assays on whole infected cells, improve the effect of the drug and validate that it is also effective for other kinds of herpes viruses.”

Search: Herpes, zoster, Epstein-Barr, varicella, cytomegalovirus, CMV, HHV8, Kaposi's sarcoma, Miguel Coll, Isentress, raltegavir, integrase inhibitor,

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (10 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.